Smoking status and SARS-CoV-2 infection severity among Lebanese adults: a cross-sectional study

Abbas Hoballah1†, Rana El Haidari2*†, Rima Badran3, Ali Jaber3, Samir Mansour4 and Linda Abou-Abbas5,6

Abstract
Background: A paradoxical hypothesis about the effect of smoking on patients infected with severe acute respiratory syndrom 2 (SARS-CoV-2) infection still exists. Furthermore, gender-discrepancy in the impact of smoking on COVID-19 severity was given little attention. Thus, the aims of the present study were to evaluate the prevalence of smoking and the COVID-19 infection severity in a sample of adult patients diagnosed with COVID-19 and to explore the relationship between smoking status and SARS-CoV-2 infection severity in the overall sample and stratified by gender.

Methods: A retrospective analytical study was conducted on patients diagnosed with COVID-19 cases between December, 2020 and April, 2021 from three leading laboratories in Lebanon. Sociodemographic characteristics, smoking status and clinical symptoms were collected. Multinomial logistic regression analysis was used to explore the relationship between smoking status and SARS-CoV-2 infection severity.

Results: A total of 901 confirmed COVID-19 cases participated in the study, 50.8% were females. The mean age of patients was 38.4 years (SD = 15.3). Of the total sample, 521 (57.8%) were current smokers. Regarding infection severity, 14.8% were asymptomatic, 69.9% had mild symptoms, while 15.3% had severe infection. In the overall sample, smoking status, smoking types and dose–response were not significantly associated with infection severity. Upon stratifying the entire sample by gender, no association was found between all the considered variables with infection severity among females. However, a significant association was found among male with mild infection compared to their asymptomatic counterparts (OR = 1.78 95% CI (1.01–3.13)). Waterpipe smoking was found to be associated with infection severity among male with mild infection (OR 2.64 (95% CI 1.32–5.27)) and severe infection 2.79, 95% CI (1.19–6.53) compared to their asymptomatic counterparts.

Conclusion: Our fundings highlight sex differences in the association between tobacco smoking and COVID-19 severity. Current tobacco smoking was not associated with SARS-CoV-2 infection severity among female patients, however, tobacco smoking, particularly waterpipe, was found to be associated with infection severity among male. Thus, the battle against smoking should continue by assisting smokers to successfully and permanently quit.

Keywords: Smoking status, SARS-CoV-2 infection severity, Lebanese adults, Cross-sectional study

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease (COVID-19), has rapidly swept the globe, producing devastating threats on global public health and economy
SARS-CoV-2 holds a higher aggressive and contagious capacity than any prior human coronavirus [2]. Tremendous efforts have been made to better understand transmission, mechanisms and pathophysiology, as well as developing new diagnostic, preventative and therapeutic measures. Studies have identified that the cell surface molecule angiotensin-converting enzyme 2 (ACE2) serves as the prominent host receptor and mediates the process of SARS-CoV-2 infection in human cells [3–5]. In particular, the SARS-CoV-2 spike (S) protein binds to the cellular ACE2 mediates the subsequent fusion between viral envelope and host cell membrane through receptor-mediated endocytosis, thereby allowing viral entry into host cells [6]. Globally, several strategies were adopted to fight SARS-CoV-2 induced alveolar damages and reduce the symptoms’ severity [7].

As this new virus spreads, more questions about COVID-19 disease severity risk factors arise. Observational studies have consistently identified several risk factors including older age, male sex and comorbidities such as cancer, hypertension, diabetes and respiratory diseases [8–10]. However, studies evaluating the impact of smoking on COVID-19 vulnerability have shown contradictory results. Whilst a protective effect existed in research conducted early during the pandemic with lower smoking prevalence among COVID-19 patients compared to the general population, a positive association was reported in other studies suggesting that smoking would worsen the SARS-CoV-2 prognosis including hospitalization in an intensive care unit, the need for mechanical ventilation, or mortality [11–14]. In addition, some studies revealed no association between smoking and SARS-CoV-2 infection [15,16].

Along with the conflicting observational evidence that a “smoker’s paradox” exists in COVID-19, several mechanisms have been proposed [17–20]. Authors postulate that nicotine would protect against COVID-19 through the SARS-CoV-2 penetration and propagation inhibition [21,22]. Within the respiratory tract and central nervous system, nicotine is thought to compete with SARS-CoV-2 for the nicotinic acetylcholine receptor binding site that works as a co-receptor for viral cell entrance resulting in a decrease in accessible viral adhesion sites [23]. To support this hypothesis, several studies were initiated to elucidate the relationship between nicotine and SARS-CoV-2 infection severity [16,24,25]. Conversely, a hypothetical relationship between smoking and severe COVID-19 symptoms can be made as smoking was consistently found to be associated with increased morbidity and mortality in a variety of respiratory infections due to its immune response’s suppressive effect [17,26]. Gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers, consequently putting smokers at higher risk of contracting SARS-CoV-2 [27,28]. It is worth noting that the majority of the published studies that falls under the scope of smoking and SARS-CoV-2 severity were conducted among hospitalized COVID-19 patients [29]. The latter represents only a minority among SARS-CoV-2 confirmed population. However, asymptomatic and clinically mild infections that do not necessitate hospitalization are more likely to occur. Thus, it would be interesting to evaluate the prevalence of smoking and to clarify the association between smoking and COVID-19 severity in a sample of COVID-19 patients that present the full spectrum of disease severity ranging from asymptomatic to severe disease level.

Lebanon, a small developing country located on the eastern shore of the Mediterranean Sea, was ranked third in the world for having the most smokers per capita for both sexes [30]. The World Health Organisation estimates of 2018 revealed that the prevalence of current tobacco smoking in Lebanon is 42.6% [31]. The most recent household survey revealed a significantly higher cigarette smoking rate in males than females (48.6% and 21.5% respectively) and a high prevalence of waterpipe smoking with 32.7% and 46.2% males and females respectively [32]. Therefore, assessing the association between smoking and COVID-19 severity in Lebanon is greatly representative and instructive. Thus, the aims of the present study were to evaluate the prevalence of smoking and the COVID-19 infection severity in a sample of adult patients diagnosed with COVID-19. In addition, we sought to explore the relationship between smoking and SARS-CoV-2 infection severity.

Materials and methods

Data source

An observational retrospective analytical study was conducted on patients diagnosed with COVID-19 at the Islamic Health Society (IHS): one of the largest non-governmental organizations in Lebanon. All the electronic laboratory records of confirmed SARS-CoV-2 cases in three IHS laboratories between December, 2020 and April, 2021 were accessed. Adult patients aged 18 years and above and who tested positive for SARS-CoV-2 by the reverse-transcriptase–polymerase chain reaction testing (RT-PCR) of nasopharyngeal swab were eligible to participate in the study. Eligible patients were contacted via phone by the IHS “Corona Call Center”, and were asked to provide an oral informed consent to participate in the study. The study protocol was approved by the Islamic Health Society Research Ethics Committee (11-21,421-SC).
Participants were asked to provide data regarding their sociodemographic characteristics (age, gender, education), weight, height, diverse comorbidities, smoking behaviors (current smoking consumption, type of tobacco, frequency and intensity of current smoking and duration of smoking), previous SARS-CoV-2 infection (symptoms, duration, and severity), treatment, and hospitalization (admission).

Smoking status was defined as never smoked (i.e. persons who had never smoked regularly), and current smokers. To explore the dose–response effect, a variable by collapsing data on smoking status and smoking duration in years was created as follows: current smokers grouped with mild smokers (≤ 10 cigarettes/day for < 15 years or > 10 cigarettes/day for < 15 years), moderate smokers (≤ 10 cigarettes/day for ≥ 15 years or > 10 cigarettes/day for < 15 years), and heavy smokers (> 10 cigarettes/day for ≥ 15 years) [16]. For waterpipe smokers, participants were grouped with mild smokers (≤ 4 waterpipe/week for < 15 years), moderate smokers (≤ 4 waterpipe/week for ≥ 15 years or > 4 waterpipe/week for < 15 years), and heavy smokers (> 4 waterpipe/week for ≥ 15 years). To calculate the cumulative dosing of cigarette/waterpipe smoking, smoking duration (in years) was multiplied by the mean number of daily cigarette packs or number of times waterpipes were used weekly.

Patients with COVID-19 were classified into three levels:

- Asymptomatic infection: absence of SARS-CoV-2 symptoms;
- Mild infection: presence of at least one SARS-CoV-2 symptoms excluding pneumonia;
- Moderate/Severe infection: presence of pneumonia and/or hospitalization for COVID-19 [16].

The sample size was calculated using the Epi Info™ tool (Center for Disease Control, Atlanta, GA, USA). Available from http://www.cdc.gov/epiinfo/. A minimal sample size of 384 was calculated assuming a priori estimated 42.6% smoking prevalence in Lebanese population [31], a confidence interval of 95%, a maximum allowable error in the prevalence of 1%, and a Lebanese population size of 4,842,000 habitants based on the latest Lebanese census data [35].

Sociodemographic and clinical characteristics of the participants were described using the mean (standard deviation) for continuous variables, and the number (percent) for qualitative variables. Categorical variables were compared in univariate analyses (Pearson chi square test) and the means of continuous variables with the Student’s t test or the one-way analysis of variance (ANOVA). Bivariate multinomial logistic regression models (overall, split by gender) were conducted to explore the association between smoking status and dosages and SARS-CoV-2 infection severity. The infection severity variable (asymptomatic, mild and severe) was considered as dependent variable using “asymptomatic” as a reference category; smoking status (smokers versus non-smokers) and dosages variables such as smoking type (non-smokers, cigarette smokers, waterpipe smokers,and dual smokers); dose–response relationship for cigarette (non-smokers, mild, moderate, heavy) and waterpipe (non-smokers, mild, moderate, heavy) were considered as independent variables. Independent variables with p-value < 0.2 were included in the model. The covariables used for each model were age, body mass index and comorbidities (no versus yes). Associations were estimated with odds ratios (ORs) along with their corresponding 95% confidence intervals. The akaike information criterion (AIC) was computed to determine how the data fit the regression model. All tests were two-sided and statistical significance was set at p-value < 0.05. The collected data was analyzed with the Statistical Package for Social Sciences software (SPSS) version 26.

A total of 901 confirmed COVID-19 cases participated in the study of whom 50.8% were females. The mean age of patients was 38.4 years (SD = 15.3). About one third of the participants (34.9%) had a university education level. Patients with underlying disease represented 31.3% of the total. Out of 901 patients, 521 (57.8%) were current smokers, out of whom 41.8% were cigarette smokers, 52.8% were waterpipe smokers and 5.4% were dual smokers. Demographic and clinical characteristics of the COVID-19 patients as per their smoking status are shown in Table 1. Smokers were more likely to be males (58.2% males vs 41.8% females) and to have a lower mean age (38.3 years) as compared to non-smokers (38.6 years). Comorbidities among smokers were higher than among non-smokers (69.1% vs 30.9%). Comparisons of demographic and clinical information between asymptomatic patients and those with mild or severe disease are shown in Table 2. Infection severity was associated with age, gender, educational level.
| Variables                      | All participants (N = 901) | Non-smoker (n = 380) | Smoker (n = 521) | p-value | Cigarette smoking (n = 218) | p-value | Waterpipe smoking (n = 275) | p-value | Cigarette and waterpipe smoking (n = 28) |
|--------------------------------|----------------------------|----------------------|------------------|---------|-----------------------------|---------|-----------------------------|---------|-------------------------------------|
| Age, years mean (SD)           | 38.4 (15.3)                | 38.6 (15.7)          | 38.3 (15.1)      | 0.73    | 3.26 (13.8)                 | 0.0001  | 33.8 (10.6)                 | 0.06    | 33.0 (12.4)                         |
| Gender                         | Male 458 (49.2)            | 155 (40.8)           | 303 (58.2)       | <0.0001 | 11 (7.6)                    | 0.25    | 26 (44.8)                    | 0.20    | 20 (71.4)                           |
| Secondary                      | Female 443 (50.8)          | 225 (59.2)           | 218 (41.8)       | 0.01    | 8 (11.8)                    | 0.05    | 32 (55.2)                    | 0.27    | 8 (28.6)                            |
| Education                      | Primary school 212 (23.5)  | 78 (36.8)            | 134 (63.2)       | 0.01    | 3 (41)                      | 0.05    | 11 (23.4)                    | 0.27    | 6 (21.4)                            |
| Middle or high school          | University or post-graduate degree 314 (34.9) | 146 (46.5)            | 168 (53.5)       | 0.01    | 7 (13.7)                    | 0.05    | 38 (23.2)                    | 0.27    | 9 (32.1)                            |
| BMI, (kg/m²) mean (SD)         | 26.5 (5.1)                 | 26.3 (5.1)           | 26.8 (5.2)       | 0.14    | 24.6 (5.9)                  | 0.001   | 26.1 (5.4)                   | 0.29    | 25.9 (3.9)                          |
| Comorbidities (yes)            | 282 (31.3)                 | 120 (42.6)           | 162 (57.4)       | 0.88    | 5 (5.6)                     | <0.0001 | 14 (22.2)                    | 0.20    | 5 (17.9)                            |
and comorbidities (p-value > 0.05). The highest mean age was found among patients who had a severe infection compared to their asymptomatic counterparts or patients with mild infection (47.0 years old for severe cases versus 36.9 years for mild and asymptomatic patients (p-value < 0.0001)). Men had more severe infection than women (17.9% versus 12.6%; p-value = 0.03). Participants with primary school were more likely to suffer from severe infection compared to their counterparts with high education level (24.5% versus 9.5% and 12.7% for Middle or high school and university educational level respectively; p < 0.0001). Results also showed that COVID-19 cases with comorbidities had high proportion of severe infection compared to their asymptomatic counterparts or patients with mild infection (49.3% versus 28.9% and 24.1% for mild and asymptomatic patients respectively; p < 0.0001) (Table 2).

Table 3 shows the COVID-19 clinical characteristics and smoking status of the study participants. Of the total patients, 14.8% were asymptomatic, 69.9% had mild symptoms, while 15.3% had severe infection. Among the symptomatic patients, the most common symptoms were headache (59.4%), muscle or bone pain (53.5%), fever (46.9%) and cough (44.2%). Results showed that no significant association between infection severity, self-reported SARS-CoV-2 symptoms, hospitalisation and cigarette smoking (p-value > 0.05). Moreover, no significant associations between infection severity, hospitalisation and waterpipe smoking were found. Regarding self-reported symptoms, on the other hand, patients who smoked had olfactory and taste disorders approximately double than non-smokers (66.9% versus 33.1%) (p-value = 0.02). Furthermore, non-smokers were more fatigued than smokers (45.8% versus 54.2%, P-value = 0.01). Patients who smoked cigarette moderately and heavily had significantly higher percentage of cough (41.3% and 53.8% for moderate and heavy smokers, respectively) compared to their mild counterparts (5.0%) (p-value = 0.04) (Table 3).

Table 4 shows adjusted ORs with 95% CI from multinomial logistic regression, with the severity groups as the dependent variable (asymptomatic group as reference), smoking status and dosages as independent variables. In the overall sample, smoking status, smoking types and dose–response were found no significant at 5% level of significance. Moreover, no significant associations between infection severity, hospitalisation and waterpipe smoking were found. Regarding waterpipe dose response relationship, moderate dose consumption was associated with infection severity among male with severe infection compared to their asymptomatic counterparts (OR = 2.48, 95% CI 1.06–5.79).

Discussion
The aim of the present study was to evaluate the prevalence of smoking in a sample of adult patients diagnosed with COVID-19 and to explore the relationship between smoking and SARS-CoV-2 infection severity. Findings showed a high tobacco smoking prevalence among the 901 SARS-CoV-2 confirmed cases. Regarding infection severity, 14.8% were asymptomatic, 69.9% had mild symptoms, while 15.3% had severe infection. In the
### Table 3  COVID-19 Clinical characteristics of the study participants by smoking status (n = 901)

| Variables                          | All participants (n = 901) | Never smoked (n = 380) | Smoker (n = 521) | p-value | Cigarette smokers (n = 218) | Waterpipe smokers (n = 275) | p-value | Cigarette and Waterpipe smoking (n = 28) |
|-----------------------------------|---------------------------|------------------------|------------------|---------|----------------------------|-----------------------------|---------|-----------------------------------------|
|                                   |                           |                        |                  |         |                           |                             |         |                                         |
| Infection severity*               |                           |                        |                  |         |                           |                             |         |                                         |
| Asymptomatic infection            | 133 (14.8)                | 63 (47.4)              | 70 (52.6)        | p-value | 1 (3.1)                   | 17 (53.1)                   | 14 (43.8)| 6 (10.3)                               |
| Mild                              |                           |                        |                  |         |                           |                             |         |                                         |
| Severe                            | 630 (69.9)                | 256 (40.6)             | 374 (59.4)       | p-value | 16 (10.8)                 | 70 (47.3)                   | 62 (41.9)| 42 (72.4)                             |
| Self-reported symptoms            |                           |                        |                  |         |                           |                             |         |                                         |
| Headache                          | 535 (59.4)                | 215 (40.2)             | 320 (59.8)       | p-value | 2 (0.9)                   | 46 (27.7)                   | 94 (92) | 74 (82)                               |
| Muscle or bone pain               | 482 (53.5)                | 205 (42.4)             | 278 (57.6)       | p-value | 10 (9.3)                  | 49 (45.8)                   | 48 (44.9)| 36 (62.1)                             |
| Fever                             | 423 (46.9)                | 188 (44.4)             | 235 (55.6)       | p-value | 10 (11.6)                 | 40 (46.5)                   | 36 (41.9)| 29 (50.0)                             |
| Cough                             | 398 (44.2)                | 182 (45.7)             | 216 (54.3)       | p-value | 4 (50)                    | 33 (41.3)                   | 43 (53.8)| 27 (46.6)                             |
| Dyspnea                           | 290 (32.2)                | 123 (42.4)             | 167 (57.6)       | p-value | 8 (11.1)                  | 28 (38.9)                   | 36 (50.0)| 15 (25.9)                             |
| Gastrointestinal disturbances     | 169 (18.8)                | 78 (46.2)              | 91 (53.8)        | p-value | 6 (16.7)                  | 14 (38.9)                   | 16 (44.4)| 11 (19.0)                             |
| Olfactory and taste disorders     | 133 (14.8)                | 44 (33.1)              | 89 (66.9)        | p-value | 1 (3.6)                   | 16 (57.1)                   | 11 (39.3)| 13 (22.4)                             |
| Fatigue                           | 96 (10.7)                 | 52 (54.2)              | 44 (45.8)        | p-value | 2 (13.3)                  | 7 (46.7)                    | 6 (40.0)| 6 (10.3)                              |
| Sore throat or rhinorrhea         | 32 (3.6)                  | 17 (53.1)              | 15 (46.9)        | p-value | 1 (16.7)                  | 3 (50.0)                    | 2 (33.3)| 2 (3.4)                               |
| Pneumonia                         | 21 (2.3)                  | 8 (38.1)               | 13 (61.9)        | p-value | 0 (0.0)                   | 2 (66.7)                    | 1 (33.3)| 2 (3.4)                               |
| Conjunctivitis                    | 8 (0.9)                   | 6 (75.0)               | 2 (25.0)         | p-value | 1 (100)                   | 0 (0.0)                     | 0 (0.0)| 0 (0.0)                               |

*p-values are based on Chi-square or Fisher’s exact test.*
### Table 3 (continued)

| Variables          | All participants (n = 901) | Never smoked (n = 380) | Smoker (n = 521) | p-value | Cigarette smokers (n = 218) | p-value | Waterpipe smokers (n = 275) | p-value | Cigarette and Waterpipe smoking (n = 28) | p-value |
|--------------------|-----------------------------|------------------------|-------------------|---------|----------------------------|---------|-----------------------------|---------|------------------------------------|---------|
|                    |                             |                        |                   |         |                            |         |                             |         |                                    |         |
|                    |                             |                        |                   |         | Mild (n = 19)               |         |                             |         | Mild (n = 58)                   |         |
|                    |                             |                        |                   |         | Moderate (n = 101)          |         |                             |         | Moderate (n = 196)              |         |
|                    |                             |                        |                   |         | Heavy (n = 93)              |         |                             |         | Heavy (n = 21)                 |         |
| Heart palpitations | 4 (0.4)                     | 2 (50.0)               | 2 (50.0)          | 1.00    | 0 (0.0)                    | 0 (0.0) | 0 (0.0)                     | 0.19    | 0 (0.0)                           | 1.00    |
|                    | 3 (0.3)                     | 0 (0.0)                | 3 (100.0)         | 0.26    | 0 (0.0)                    | 0 (0.0) | 1 (0.0)                     | 0.52    | 0 (0.0)                           | 2 (1.0) |
| Shortness of breath| 128 (14.2)                  | 58 (45.3)              | 70 (54.7)         | 0.33    | 2 (63.3)                   | 14 (43.8)| 16 (50.0)                   | 0.68    | 9 (16.4)                         | 24 (12.7)|
|                    |                             |                        |                   |         |                             |         |                             |         |                                    |         |
| Hospitalisation (yes) | 128 (14.2)                  | 58 (45.3)              | 70 (54.7)         | 0.33    | 2 (63.3)                   | 14 (43.8)| 16 (50.0)                   | 0.68    | 9 (16.4)                         | 24 (12.7)|
|                          |                             |                        |                   |         |                             |         |                             |         |                                    |         |

n frequency, % percentage

P-value '0.05 is considered significant

*Infection severity: asymptomatic infection: without SARS-CoV-2 symptoms; mild infection: at least one SARS-CoV-2 symptoms excluding pneumonia; severe infection: presence of 3 or more SARS-CoV-2 symptoms with pneumonia and/or hospitalisation for SARS-CoV-2
overall sample, smoking status, smoking types and dose–response were not significantly associated with infection severity. Upon stratifying the entire sample by gender, no association was found between all the considered variables with infection severity among females. However, a significant association was found among male with mild infection compared to their asymptomatic counterparts. Waterpipe smoking was found to be associated with infection severity among male with mild infection and severe infection compared to their asymptomatic counterparts.

In our sample, smoking prevalence was 57.8% exceeding the WHO prevalence estimates of current tobacco smoking in 2018 (42.6%) [31], as well as the prevalence of tobacco smoking reported among the hospitalized COVID-19 patients of Khalil et al. study (42.3%) [33]. Results also revealed a high prevalence of tobacco smoking among male participants (58.2%) compared to their females counterparts (41.8%) which also exceeded the WHO prevalence estimates of current tobacco (49.2% and 35.9% males and females respectively) [31]. In our sample, only 14.8% of COVID-19 cases were asymptomatic. A possible explanation of the high tobacco smoking prevalence and the low prevalence of asymptomatic cases is that PCR testing is likely to be limited to vulnerable symptomatic subgroups, with the potential for these groups to include an overrepresentation of current tobacco smokers. Moreover, due to the increased prevalence of COVID-19-related symptoms, such as cough, increased sputum production, or altered taste or smell, current tobacco smokers may be more likely to present for testing, raising the denominator in comparisons to non-smokers and potentially inflating the prevalence of SARS-CoV-2 infection among current smoker. Thus, the

### Table 4

| Variables | All (N = 901) | Males | Females |
|-----------|--------------|-------|---------|
| | Mild versus asymptomatic ORa (95% CI) | Severe versus asymptomatic ORa (95% CI) | Mild versus asymptomatic ORb (95% CI) | Severe versus asymptomatic ORb (95% CI) |
| Smoking status | 1.23 (0.81–1.85) | 1.07 (0.62–1.83) | **1.78 (1.01–3.13)** | 1.44 (0.70–2.96) |
| AIC | 1249 | 685 | 571 |
| Smoking type | | | |
| Non-smoker | 1.00 | 1.00 | 1.00 | 1.00 |
| Cigarette smoker | 1.11 (0.69–1.79) | 0.80 (0.43–1.48) | 1.65 (0.90–3.03) | 1.16 (0.53–6.53) |
| Waterpipe smoker | 1.42 (0.90–2.24) | 1.59 (0.88–2.87) | **2.64 (1.32–5.27)** | **2.79 (1.19–6.53)** |
| Dual smokers | 3.03 (0.70.13.2) | 1.38 (0.18–10.30) | 3.20 (0.69–14.80) | 1.75 (0.22–13.8) |
| AIC | 1249 | 685 | 571 |
| Dose–response relationship | | | |
| Cigarette smoking | | | |
| Non-smoker | 1.00 | 1.00 | 1.00 | 1.00 |
| Mild | 0.69 (0.17–2.83) | 0.80 (0.13–4.92) | 0.98 (0.17–5.47) | 0.65 (0.06–6.20) |
| Moderate | 0.94 (0.44–2.00) | 0.72 (0.26–1.99) | 1.66 (0.60–4.56) | 1.02 (0.25–4.13) |
| Heavy | 2.01 (0.56–7.18) | 0.83 (0.12–5.71) | 1.55 (0.36–6.69) | 1.21 (0.14–9.98) |
| AIC | 1248 | 685 | 569 |
| Waterpipe smoking | | | |
| Non-smoker | 1.00 | 1.00 | 1.00 | 1.00 |
| Mild | 2.11 (0.24–18.24) | 1.94 (0.16–22.46) | – | – |
| Moderate | 0.86 (0.45–1.63) | 0.77 (0.30–1.95) | 1.93 (0.97–3.84) | **2.48 (1.06–5.79)** |
| Heavy | 3.15 (0.89–11.12) | 2.61 (0.57–11.83) | 4.61 (0.58–36.85) | 3.07 (0.26–36.10) |
| AIC | 1249 | 685 | 571 |

Significant results are presented on bold

Cigarette smoking: Mild smokers: ≤ 10 cigarettes/day for < 15 years, moderate smokers: ≥ 10 cigarettes/day for < 15 years and ≥ 10 cigarettes/day for ≥ 15 years, and heavy smokers: > 10 cigarettes/day for ≥ 15 years. Waterpipe smoking: Mild smokers: ≤ 4 waterpipe/week for < 15 years, moderate smokers: > 4 waterpipe/week for < 15 years, and heavy smokers: > 4 waterpipe/week for ≥ 15 years

AIC the akaike information criterion, CI confidence interval, OR odds ratio

a Models adjusted for age, gender, BMI, and comorbidities

b Models adjusted for age, BMI, and comorbidities
estimation of the SARS-CoV-2 infection positivity rates from random samples are more useful.

Findings showed that male patients present severe infection more than female. Based on previous studies, evidence suggests that male patients are the most susceptible to SARS-CoV-2 infection, which is supported by our data [36–38]. In a large global meta-analysis of 107 COVID-19 reports, Peckham et al. demonstrate that male sex is associated with a significantly increased risk of intensive treatment unit admission and higher odds of death compared to females [36]. Capuano et al. established that this sex difference may be related to several factors such as activity of the immune system and its modulation by sex hormones, coagulation pattern, and preexisting cardiovascular diseases as well as effects deriving from smoking and drinking habits [37].

No significant association was found between the smoking status and infection severity in the overall sample. This result was consistent with other studies [15, 16]. However, upon stratifying the sample by gender, multinomial logistic regression models revealed a significant association among male with mild infection compared to their asymptomatic counterparts (OR = 1.78, 95% CI (1.01–3.13)), a recent study conducted in Lebanon among 743 hospitalized COVID-19 patients revealed a high smoking prevalence (42.3%) combined with worse prognosis as well as a higher mortality rate in smoking patients [33]. A gender-discrepancy in the association of smoking on COVID-19 mortality rates was also reported. Remarkably, current smoking status was associated with higher vulnerability to death among COVID-19 hospitalized male patients, while it does not affect ICU admission or survival outcomes among hospitalized COVID-19 female patients as compared to their non-smoker counterpart [33]. More research on the potential gender-discrepancy in the effect of smoking on COVID-19 severity while accounting for smoking dosages are still needed.

Since SARS-CoV-2 infection primarily targets the lungs, smoking-related lung disorders overlap with COVID-19 respiratory comorbidities such as chronic bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD) [42]. A recent study revealed that the activation of the ACE-2 in mice lungs following e-cigarette vapor exposure is gender-specific [43]. Male mice had a more pronounced nicotine-dependent increase in lung ACE-2 expression than female mice, which can influence COVID-19 severity [43]. Thus, the observed significant repercussions of smoking among men in our study could be explained by the fact that this group had a higher risk of developing lung problems as a result of tobacco smoking. Furthermore, future research must be highlight the different factors that can threaten people to infected with COVID-19 infection such as the social practices of waterpipe use. Interestingly, our results are in line with recent study who revealed that current smoking status reduces survival rate in male patients but it does not affect survival outcomes among hospitalized female patients [33]. Particularly, waterpipe smoking among males was associated with mild infection (OR 2.64, 95% CI (1.32–5.27)) and severe infection (OR 2.79, 95% CI (1.19–6.53) compared to their asymptomatic counterparts. Regarding waterpipe dose response relationship, moderate dose consumption was associated with infection severity among male with severe infection compared to their asymptomatic counterparts (OR = 2.48, 95% CI 1.06–5.79). However, a closer look to the adjusted odds ration revealed an association that did not reach statistical significance due to the low sample size in subcategories. Overall, our results suggest adding tobacco smoking particularly waterpipe as a risk factor for worse COVID-19 prognosis among males and highlight the importance of waterpipe smoking cessation.

The present study has several limitations. Due to the observational nature of the study and the cross-sectional design, we cannot infer any causal relationship between smoking habits and SARS-CoV-2 infection severity. Furthermore, smoking habits and SARS-CoV-2 symptoms were self-reported; consequently, recall bias might have led to misclassification of the exposure. Lastly, the sample with an acceptable geographical coverage reflecting the distribution of SARS-CoV-2 infection in Lebanon was not entirely representative of the Lebanese population.

Conclusions

Our findings highlight sex differences in the association between tobacco smoking and COVID-19 severity. Current tobacco smoking was not associated with SARS-CoV-2 infection severity among female patients, however, tobacco smoking, particularly waterpipe, was found to be associated with infection severity among male. Thus, there is a growing need to support the WHO statement that ‘smokers are at higher risk of developing severe disease and death’ and the battle against smoking should continue, by assisting smokers to successfully and permanently quit [44]. Smoking cessation should be incorporated into public health campaigns especially during the SARS-CoV-2 pandemic and in the aftermath. Future studies should take into consideration social factors that affect smoking (e.g. participation in waterpipe smoking at the same time, dual smokers of cigarette and waterpipe, using several type of tobacco) in addition to comparing patients with COVID-19 to uninfected people.
Abbreviations
BMI: Body Mass Index; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; CI: Confidence interval; SD: Standard deviation; RT-PCR: Reverse transcription polymerase chain reaction.

Acknowledgements
The authors are grateful to all the health care workers from the Islamic Health Society who collaborated in this study and to all participants that voluntarily took part in the study. And the authors thank Fatima Haidar (Lebanese university) for editorial assistance.

Author contributions
Conceptualization, RH, RB and AJ; methodology, AH, RH, RB and AJ; software, SM and RH; validation, AH, LAA, RH, RB and AJ; formal analysis, AH, RH, and LAA; investigation, RB and AJ; resources, AH, RH; data curation, RH and AH; writing—original draft preparation, RH; LAA and AH writing—review and editing, RH; LAA and AH visualization, AH, SM, LAA, RH, RB and AJ; supervision, LAA, project administration, AH, RH, SM, RB and AJ. All authors read and approved the final manuscript.

Funding
This research received no external funding.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Islamic Health Society on 1 May 2021 (protocol code 150521-02). Informed oral consent was obtained from all subjects involved in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interest.

Author details
1 General Director of Islamic Health Society, Baabda, Lebanon. 2 Department of Research, Islamic Health Society, Baabda, Lebanon. 3 Department of Psychological Health, Islamic Health Society, Baabda, Lebanon. 4 Department of Informatics, Islamic Health Society, Baabda, Lebanon. 5 Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. 6 Epidemiological Surveillance Program, Ministry of Public Health, Beirut, Lebanon.

Received: 5 May 2022   Accepted: 14 September 2022
Published online: 24 September 2022

References
1. Severe Acute Respiratory Syndrome (SARS) [Internet]. [cited 2022 Mar 29]. Available from: https://www.who.int/westernpacific/health-topics/severe-acute-respiratory-syndrome
2. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21(1):224.
3. Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B. 2021;11(1):1–12.
4. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.
5. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
6. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.
7. Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35.
8. Schlesinger S, Neuenschwander M, Lang A, Paflk K, Kuss O, Herder C, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64(7):1480–91.
9. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;10(1):8562.
10. Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. The Lancet Regional Health - Europe [Internet]. 2021 Sep 1 [cited 2022 Mar 29]. Available from: https://www.thelancet.com/journals/lanepid/article/PIIS25837742(21)00135-6/fulltext
11. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
12. Cattaruzza MS, Zagà V, Gallus S, D’Argenio P, Gorini G, Dorfman D. Angiotensin and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature. Acta Biomed. 2020;91(2):106–12.
13. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–41.
14. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living evidence review with Bayesian meta-analyses (version 7). Addiction. 2021;116(8):1319–68.
15. Vallarta-Robledo JR, Sandoval JL, Baggio S, Salamun J, Jacquieroz F, Sprechbach H, et al. Negative association between smoking and positive SARS-CoV-2 testing: results from a Swiss outpatient sample population. Front Public Health. 2021;9. https://doi.org/10.3389/fpubh.2021.731981.
16. Prinelli F, Bianchi F, Drago G, Ruggieri S, Sojaic J, Esusethasan N, et al. Association between smoking and SARS-CoV-2 infection: cross-sectional study of the EPICOR2019 internet-based survey. JMIR Public Health Surveill. 2021;7(4):e27091.
17. Jiang C, Chen Q, Xie M. Smoking increases the risk of infectious diseases: a narrative review. Tob Induc Dis. 2020;14(18):60.
18. Peng F, Lei S, Zhang Q, Zhong Y, Wu S. Smoking is correlated with the prognosis of coronavirus disease 2019 (COVID-19) patients: an observational study. Front Physiol. 2021;12:634842.
19. Shastri MD, Shukla SD, Chong WC, Rajendra KC, Dua K, Patel RP, et al. Smoking and COVID-19: What we know so far. Respirolog. 2021;176:106237.
20. Haddad C, Buoulmhab S, Sacre H, Salameh P. Smoking and COVID-19: a scoping review. Tob Use Insights. 2021;14:1179173X21994612.
21. Zamorano Cuervo N, Grandvaux N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2021;9.e61390.
22. Gadaneck LR, McSweeney KR, Quadriah T, Ali B, Zulli A, Apostolopoulos V. Can SARS-CoV-2 virus use multiple receptors to enter host cells? Int J Mol Sci. 2021;22(3):992.
23. Dormoy V, Perotin J-M, Gossel P, Massos U, Polette M, Deslée G. Nicotinic receptors as SARS-CoV-2 spike co-receptors? Med Hypotheses. 2022;158:110741.
24. Duszyński T, Fadel W, Wools-Kaloustian KK, Dixon BE, Yiannoutsos C, Halverson PK, et al. Association of health status and nicotine consumption with SARS-CoV-2 positivity rates. BMC Public Health. 2021;21(1):1786.
25. Ismail N, Hassan N, Abd Hamid MNH, Yusof UN, Khamal NR, Omar MA, et al. Association of smoking and severity of COVID-19 infection among 5,889 patients in Malaysia: a multi-center observational study. Int J Infect Dis. 2022;111(6):189–96.
26. He Y, Sun J, Ding X, Wang Q. Mechanisms in which smoking increases the risk of COVID-19 infection: a narrative review. Iran J Public Health. 2021;50(3):431–7.
27. Wark PAB, Pathinayake PS, Kaiko G, Nichol K, Ali A, Chen L, et al. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology. 2021. https://doi.org/10.1111/resp.14003.

28. Smith JC, Sausville EL, Grish V, Yuan ML, Vasudevan A, John KM, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53(5):S14-S29.e3.

29. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;20(18).20.

30. Abdulrahim S, Jawad M. Socioeconomic differences in smoking in Jordan, Lebanon, Syria, and Palestine: a cross-sectional analysis of national surveys. PLoS ONE. 2018;13(1): e0189829.

31. Prevalence of current tobacco use (% of adults) - Lebanon [Data [Internet]. [cited 2022 Apr 6]. Available from: https://data.worldbank.org/indicator/SH.PRV.SMK?locations=LB.

32. Nakkash R, Khader Y, Chalaki A, Abra R, Abu-Rmeileh NME, Mostafa A, et al. Prevalence of cigarette and waterpipe tobacco smoking among adults in three Eastern Mediterranean countries: a cross-sectional household survey. BMJ Open. 2022;12(3): e055201.

33. Khalil A, Dingra R, Al-Mulki J, Hassoun M, Alexis N. Questioning the sex-specific differences in the association of smoking on the survival rate of hospitalized COVID-19 patients. PLoS ONE. 2021;16(8): e0255692.

34. Baddoura R, Wehbeh-Chidiac C. Prevalence of tobacco use among the adult Lebanese population. Eastern Mediterr Health J. 2001;7(4–5):819–28.

35. Central Administration of Statistics-Population [Internet]. [cited 2021 Nov 10]. Available from: http://www.cas.gov.lb/index.php/demographic-and-social-en/population-en.

36. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.

37. Capuano A, Rossi F, Paolillo G. COVID-19 kills more men than women: an overview of possible reasons. Front Cardiovasc Med. 2020;17(7):131.

38. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020 https://doi.org/10.3389/fpubh.2020.00152.

39. Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. Endocr Rev. 2012;33(1):1–47.

40. Camp PG, Coxson HO, Levy RD, Pillai SG, Anderson W, Vestbo J, et al. Sex differences in emphysema and airway disease in smokers. Chest. 2009;136(6):1480–8.

41. Haghani A, Arpawong TE, Kim JK, Lewinger JP, Finch CE, Crimmins E. Female vulnerability to the effects of smoking on health outcomes in older people. PLoS ONE. 2020;15(6): e0234015.

42. Das AB. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing. BMC Med Genomics. 2021;17(14):226.

43. Lallai V, Manca L, Fowler CD. E-cigarette vape and lung ACE2 expression: implications for coronavirus vulnerability. Environ Toxicol Pharmacol. 2021;186: 103656.

44. WHO statement: Tobacco use and COVID-19 [Internet]. [cited 2022 Apr 6]. Available from: https://www.who.int/news/item/11-05-2020-who-statement-tobacco-use-and-covid-19.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.